Loading...
Loading...
India's nicotine imports from FRANCE total $283 across 1 shipments from 1 foreign suppliers. PIERRE FABRE MEDICAMENT leads with $283 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include RAPTIM RESEARCH PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for nicotine โ a concentrated sourcing relationship with select suppliers from FRANCE.

PIERRE FABRE MEDICAMENT is the leading Nicotine supplier from FRANCE to India, with import value of $283 across 1 shipments. The top 5 suppliers โ PIERRE FABRE MEDICAMENT โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PIERRE FABRE MEDICAMENT | $283 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | RAPTIM RESEARCH PRIVATE LIMITED | $283 | 1 | 100.0% |
FRANCE โ India trade corridor intelligence
As of April 2026, the France to India shipping corridor is operating efficiently. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are experiencing normal congestion levels. Freight rates have stabilized, and the exchange rate between the Euro and the Indian Rupee remains favorable for importers. Air freight services are also operating smoothly, with no significant delays reported.
The Production-Linked Incentive (PLI) scheme, introduced in 2024, aims to boost domestic manufacturing and reduce import dependency. While this initiative encourages local production, it may impact the volume of finished nicotine formulation imports from France. However, the specialized nature of certain nicotine formulations may continue to necessitate imports, even with the push for self-reliance.
India and France share a robust trade relationship, with ongoing negotiations to enhance bilateral trade, including the pharmaceutical sector. Discussions on Free Trade Agreements (FTAs) and mutual recognition of Good Manufacturing Practices (GMP) are underway, aiming to facilitate smoother trade processes and strengthen pharmaceutical trade ties.
For a shipment of nicotine formulations from France to India, the estimated landed cost per unit is calculated as follows:
This estimate is based on the current exchange rate and standard shipping costs.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing nicotine into India requires compliance with the Drug and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs, including nicotine formulations, be registered with them. The registration process involves submitting Form 40 or 41, depending on the nature of the product, along with necessary documents such as a Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The timeline for import drug registration can vary but typically ranges from 6 to 12 months. Nicotine formulations under HS Code 30049099 are subject to these registration requirements.
Imported nicotine formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with the Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is also mandatory. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or re-exportation.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing nicotine formulations, emphasizing enhanced quality control and compliance with international standards. The Production-Linked Incentive (PLI) scheme introduced in 2024 has incentivized domestic production, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and France have facilitated smoother trade processes, including mutual recognition of Good Manufacturing Practices (GMP), thereby streamlining import procedures.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished nicotine formulations primarily due to the demand for patented or branded products not manufactured domestically. Specific dosage forms, such as transdermal patches or controlled-release tablets, may not be produced locally, necessitating imports. The domestic capacity to produce these specialized formulations is limited, leading to a dependency on imports. The market size for nicotine formulations in India is substantial, with a growing number of consumers seeking smoking cessation aids.
The Basic Customs Duty (BCD) for nicotine formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) applicable is 12%. There are no exemptions or concessional rates for imports from France, and no anti-dumping duties are imposed. The total landed duty percentage is approximately 32%.
India sources nicotine formulations from France due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. French manufacturers often hold patents for innovative nicotine delivery systems, providing a competitive advantage. While other suppliers like China, Germany, and the US also export nicotine formulations to India, France's reputation for quality and innovation makes it a preferred source. France's share in India's nicotine formulation imports is significant, reflecting its competitive position.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports nicotine formulations from France due to the availability of patented products, specialized dosage forms, and technology-licensed products that are not manufactured domestically. Specific formulations, such as transdermal patches or controlled-release tablets, may be unique to French manufacturers, fulfilling market needs that domestic producers cannot meet.
Compared to other origins like China, Germany, and the US, France offers a competitive advantage in terms of quality, regulatory compliance, and reliability. French manufacturers adhere to stringent quality standards and have a reputation for producing innovative nicotine delivery systems. While other countries may offer lower prices, France's commitment to quality and compliance with international standards makes it a preferred source for nicotine formulations.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to supply chain disruptions, highlighting the need for strategic sourcing and risk management.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Nicotine suppliers from FRANCE to India include PIERRE FABRE MEDICAMENT. The leading supplier is PIERRE FABRE MEDICAMENT with import value of $283 USD across 1 shipments. India imported Nicotine worth $283 USD from FRANCE in total across 1 shipments.
India imported Nicotine worth $283 USD from FRANCE across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Nicotine sourced from FRANCE include RAPTIM RESEARCH PRIVATE LIMITED. The largest buyer is RAPTIM RESEARCH PRIVATE LIMITED with $283 in imports across 1 shipments.
The total value of Nicotine imports from FRANCE to India is $283 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists